PharmaSUG 2026 - Paper PO-122

Implementation of Quality Tolerance Limits in Statistical Programming

Yang Gao, Pfizer Inc.

ABSTRACT

Quality Tolerance Limits (QTLs), as outlined in ICH GCP E6(R2), support clinical trials by proactively identifying systematic issues that may compromise participant safety or the reliability of trial outcomes. Required for all clinical studies, QTLs are fundamental to protecting trial integrity, safeguarding participants, and maintaining the credibility of study endpoints. To meet these regulatory expectations, sponsors must select critical parameters and set well-justified thresholds that align with the study's primary objectives. QTLs function as early warning indicators, enabling study teams to respond promptly and effectively with mitigation strategies when deviations are detected.

Implementing QTLs is a collaborative, cross-functional effort in which statistical programmers play an important role throughout the QTL lifecycle—particularly in ongoing monitoring and final reporting. This paper highlights key considerations from a statistical programming perspective and presents a hypothetical study illustrating effective application of QTLs within a pharmaceutical organization.

QTL DEFINITION AND PURPOSE

A QTL is a predefined threshold for a trial parameter that serves as an early warning indicator of potential systematic issues that could affect participant safety or the reliability of trial outcomes. By helping manage risk and enabling timely mitigation, QTLs support overall study quality and can prevent downstream problems. Deviations from these limits during a trial may signal underlying concerns that require prompt evaluation to determine whether corrective action is warranted.

QTLs should be established during protocol development and finalized before the first participant's first visit (FPFV). They must then be monitored and assessed regularly throughout the trial. In accordance with ICH E6(R2), significant deviations from QTLs—and the remedial actions taken—must be documented in the Clinical Study Report (CSR). QTL monitoring provides early warning signals of risks to trial quality, enabling timely investigation and mitigation that can minimize, or even eliminate, potential impacts.

QTL PROCESS

The QTL process described in this framework comprises three key stages: Define, Monitor, and Report. Successful implementation requires close collaboration among clinical, statistical, programming, and quality teams. QTL parameters and thresholds are defined once a draft protocol is available. Early involvement of medical and statistical experts with relevant experience, analysis of historical data, simulations and modeling, and careful consideration of known or anticipated risk factors are essential—while ensuring that the study's statistical power remains uncompromised. This stage also includes developing a QTL monitoring plan that specifies the review timeframe, frequency, and data sources for ongoing monitoring.

During the trial, periodic reporting is performed in accordance with the monitoring plan. Programmers develop analysis algorithms based on the defined QTL parameters, identify the required datasets and variables, and address data-related challenges. Reports are generated at the planned frequency and shared with the team to confirm whether QTLs remain within limits. These reports support interpretation of

results and detection of threshold breaches. Deviations are investigated promptly, and corrective actions are implemented as needed.

After trial completion, if any breach is identified, the programming team prepares a summary of QTL deviations. Significant deviations and the corresponding actions are documented in the CSR. QTL implementation should be consistent with ICH E6 guidance and industry best practices for measuring and monitoring clinical trial quality.

CONSIDERATIONS FOR DEFINING QTL PARAMETERS

QTLs should be established at the trial level during the planning phase. Parameters may include counts, proportions, or event rates and should be selected carefully—ideally aligned with critical-to-quality factors. Defining too many QTLs can dilute their impact and limit the time available to investigate and address each underlying driver.

Key considerations when defining QTL parameters include:

- Trial design: Study type and complexity help determine which risks require monitoring.
- Number of participants: Sample size influences statistical power and tolerance for variability.
- Number of sites: More sites may increase operational variability.
- Trial duration: Longer studies may be more susceptible to participant discontinuation.
- Recruitment rate: Slow or inconsistent enrollment may indicate feasibility risk.
- Trial population: Specific populations may require tailored thresholds.

When defining QTLs, document the following elements:

- Parameter and description: Clearly define the QTL and its scope.
- Threshold(s): Set limits that trigger evaluation when exceeded.
- Justification: Document the rationale for selecting the parameter and threshold(s).
- Action plan: Describe the process to follow if a threshold is breached.
- Algorithm: Specify how the parameter is calculated.
- Monitoring plan: Define the schedule, data sources, and frequency for review.

When establishing QTL parameters and limits, the study team should review historical studies with similar objectives, as data from comparable trials can provide valuable guidance. Because QTLs are tailored to the medical and statistical characteristics of each trial, previously implemented QTLs and their defining attributes can serve as a useful starting point. It is also important to align QTL parameters with the study's primary and secondary objectives. To help select appropriate thresholds, simulations may be conducted to evaluate scenarios and their potential impact on statistical power.

QTL IMPLEMENTATION – A HYPOTHETICAL STUDY

This hypothetical study illustrates how QTLs can be applied in a clinical trial designed to assess the safety and tolerability of an investigational treatment in adolescent and pediatric populations.

Parameter	Justification for Parameter	Quality Tolerance Limit (QTL)	Justification for QTL	Planned Mitigation Actions
Participants have received treatment, on	The HA requires this study to include at least XXX participants who, on	XX%	Month-to-month variation is expected, particularly among	Monitor participant dosing frequency monthly,

average, at least once per month	average, have received treatment for the condition at least once per month over the past 6 months, and at least XX participants who, on average, have received treatment for the condition at least once per month over the past 12 months.		participants with seasonal conditions. However, participants with persistently low use of the study drug may not be appropriate to continue in the study.	communicate findings promptly to sites, and take appropriate action if participants fail to meet the criteria.

Based on the defined parameters and thresholds, the programming team used the most current data to calculate the following metrics:

- Number of participants who, on average, received treatment for the condition at least once per month over the past 6 months
- Number of participants who, on average, received treatment for the condition at least once per month over the past 12 months
- Participant listing showing monthly doses and the 6-month and 12-month average dosing frequency

CONCLUSION

QTL parameters are essential to maintaining trial integrity, safeguarding participants, and supporting valid study endpoints. In accordance with ICH E6(R2), QTLs must be established for every clinical study. Pharmaceutical organizations and their service partners should align on QTL definitions and expectations to identify key parameters, set appropriate thresholds, establish tracking and reporting processes, and implement mitigation strategies throughout the clinical trial lifecycle.

The QTL framework is inherently cross-functional, with the programming team playing a pivotal role at each stage. Statistical programming contributes to QTL definition, delivers routine QTL outputs to support monitoring of potential breaches, and prepares CSR-ready summaries of QTL deviations and associated actions when deviations occur.

REFERENCES

Gilbert S. A. 2020. “Implementing Quality Tolerance Limits at a Large Pharmaceutical Company”. *PharmaSUG,* SA-284
Bhagat R, etc. 2021. "Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development". *Therapeutic Innovation & Regulatory Science*, 55:251-261
Sikdar D, etc. 2022 “Quality Tolerance Limits: Statistical and Programming Consideration”. *PHUSE*, AR01
Balagonda M, etc 2023. “Quality Tolerance Limits – More Critical Aspects of Clinical Trials with Much Less Visibility”. *PHUSE*, AR03
What Are Quality Tolerance Limits (QTLs) and Why Are They Important.
https://www.theavocagroup.com/what-are-quality-tolerance-limits-qtls-and-why-are-they-important/

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the author at:

Name: Yang Gao
Enterprise: Pfizer Inc.
Address: 401 N Middletown Rd, Pearl River, NY 10965
E-mail: yang.gao2@pfizer.com
Web: www.pfizer.com

Any brand and product names are trademarks of their respective companies.
SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.